RogerKennethCadyMD

Family Medicine • Bothell, WA

Headache Medicine

CEO at Headache Care Center and Vice President of Neurology, Alder BioPharmaceuticals

Join to view full profile

Dr. Cady is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cady's full profile

Already have an account?

Office
11804 N Creek Pkwy S
Bothell, WA 98011
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (La Crosse)Residency, Family Medicine, 1977 - 1980
Mayo Clinic College of MedicineClass of 1977

Certifications & Licensure

MO State Medical License 1986 - 2025
WA State Medical License 2017 - 2021
WI State Medical License 1978 - 2017

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers Start of enrollment: 2004 May 01
Completed
Phase 4
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. Start of enrollment: 2005 Dec 01
Completed
Phase 2
Two Rizatriptan Prescribing Portions for Treatment of Migraine Start of enrollment: 2006 Dec 01
Completed
Phase 4
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Start of enrollment: 2006 Oct 01
Terminated
Phase 4
Staccato Prochlorperazine in Migraine (in Clinic) Start of enrollment: 2005 Mar 01
Completed
Phase 2
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines Start of enrollment: 2008 Aug 01
Completed
Phase 2
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine Start of enrollment: 2008 Feb 01
Completed
Staccato Loxapine in Migraine (Out Patient) Start of enrollment: 2009 Jan 01
Completed
Phase 2
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine Start of enrollment: 2009 Aug 01
Completed
Phase 4
"Completeness of Response" Following Treatment With Treximet™ for Migraine Start of enrollment: 2009 Jun 01
Completed
Phase 4
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Start of enrollment: 2010 May 01
Terminated
Phase 4
Calcitonin Gene-related Peptide Levels in Chronic Migraine Start of enrollment: 2010 Jun 01
Completed
Phase 4
Treximet in the Treatment of Chronic Migraine Start of enrollment: 2010 Sep 01
Completed
Phase 4
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine Start of enrollment: 2010 Dec 01
Completed
Phase 4
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet Start of enrollment: 2011 May 01
Completed
Phase 4
A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines Start of enrollment: 2013 Apr 01
Completed
Phase 2
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Start of enrollment: 2014 Apr 01
Completed
Phase 4
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine Start of enrollment: 2014 Aug 01
Completed
Phase 2
Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches Start of enrollment: 2014 Jul 01
Completed
Phase 2
A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

37 citations
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase Activating Peptide
Cristina Moldovan Loomis, Benjamin H. Dutzar, Ethan W. Ojala, Lee Hendrix, Charlie Karasek, Michelle Scalley-Kim, Jenny Mulligan, Pei Fan, Jens J. Billgren, Vanessa Li...> ;The Journal of Pharmacology and Experimental Therapeutics. 2019 Jan 14
7 citations
Qualitative Change in Migraine Prevention
Roger Cady> ;Headache. 2018 Jul 1
16 citations
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute trea...
Sagar Munjal, Elimor Brand-Schieber, Kent Allenby, Egilius L.H. Spierings, Roger Cady, Alan M. Rapoport> ;The Journal of Headache and Pain. 2017 Mar 1
20 citations
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-es...
Roger Cady, Sagar Munjal, Ryan J. Cady, Heather R. Manley, Elimor Brand-Schieber> ;The Journal of Headache and Pain. 2017 Feb 7
142 citations
Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.
Stephen D. Silberstein, Anne H. Calhoun, Brian M. Grosberg, Roger Cady, Stefanie Dorlas, Kristy A. Simmons, Chris Mullin, Eric Liebler, Peter J. Goadsby, Joel R. Saper...> ;Neurology. 2016 Aug 2
4 citations
Managing migraine by patient profile: role of frovatriptan.
Roger Cady, Kathleen Farmer> ;Patient Preference and Adherence. 2016 Apr 5
254 citations
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun, David W. Dodick, Stephen D. Silberstein, Peter J. Goadsby, Uwe Reuter, Messoud Ashina, Joel Saper, Roger Cady, Yun Chon, Julie Dietrich, Robert A. Lenz> ;The Lancet. Neurology. 2016 Apr 1
60 citations
A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360 ® as Acute Treatment for Chronic Migraine
Roger Cady, Joel Saper, Kent Dexter, Heather R. Manley> ;Headache. 2015 Jan 1
43 citations
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET St...
Roger Cady, Peter McAllister, Egilius L.H. Spierings, John C. Messina, Jennifer Carothers, Per Gisle Djupesland, Ramy A. Mahmoud> ;Headache. 2015 Jan 1
19 citations
A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatm...
Roger Cady> ;Expert Opinion on Drug Delivery. 2015 Aug 12
1 citations
Symptomatic Overlap and Therapeutic Opportunities in Primary Headache.
Roger Cady, Sandy Yacoub Garas, Ketu Patel, Andrew R. Peterson, Richard P. Wenzel> ;Journal of Pharmacy Practice. 2015 Aug 1
42 citations
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study...
Stewart J. Tepper, Roger Cady, Stephen D. Silberstein, John C. Messina, Ramy A. Mahmoud, Per Gisle Djupesland, Paul Shin, Joao Siffert> ;Headache. 2015 May 1
73 citations
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi, Ying Zhang, Saheeda Jackson, Roger Cady, Christopher Lines, W. Joseph Herring, Kathryn M. Connor, David Michelson> ;Cephalalgia. 2015 Apr 1
31 citations
Long-Term Efficacy of a Double-Blind, Placebo-Controlled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the Tx360 ® Device fo...
Roger Cady, Joel Saper, Kent Dexter, Ryan J. Cady, Heather R. Manley> ;Headache. 2015 Apr 1
8 citations
Acupuncture in the Treatment of Headache: A Traditional Explanation of an Ancient Art
Roger Cady, Kathleen Farmer> ;Headache. 2015 Mar 1
177 citations
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
Kristina M. Fanning, Daniel Serrano, Michael L. Reed, Roger Cady, Dawn C. Buse, Richard B. Lipton> ;Neurology. 2015 Feb 17
6 citations
The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.
Roger Cady> ;Expert Opinion on Pharmacotherapy. 2015 Aug 10
Erratum. Correction to: The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.
Cady R> ;Expert Opin Pharmacother. 2015-01-01
8 citations
Red flags and comfort signs for ominous secondary headaches.
Roger Cady> ;Otolaryngologic Clinics of North America. 2014 Apr 1
135 citations
Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study.
Peter J. Goadsby, Brian M. Grosberg, Alexander Mauskop, Roger Cady, KA Simmons> ;Cephalalgia. 2014 Mar 7
Chronic migraine in women.
Roger K. Cady> ;The Journal of Family Practice. 2014 Feb 1
37 citations
An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic m...
Roger Cady, Ira M. Turner, Kent Dexter, M.E. Beach, Ryan J. Cady, Paul L. Durham> ;Headache. 2014 Feb 1
7 citations
Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.
Stephen H. Landy, Roger Cady, Andrew Nelsen, Jonathan White, M. Chris Runken> ;Headache. 2014 Apr 1
7 citations
SumaRT/Nap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study
Roger Cady, Phillip O'Carroll, Kent Dexter, Frederick G. Freitag, Candace L. Shade> ;Headache. 2014 Jan 1
10 citations
Treatment of Chronic Migraine: A 3‐Month Comparator Study of Naproxen Sodium vs SumaRT/Nap
Roger Cady, Robert Nett, Kent Dexter, Frederick G. Freitag, M.E. Beach, Heather R. Manley> ;Headache. 2014 Jan 1
Join now to see all

Journal Articles

Qualitative Change in Migraine Prevention?
Richard B Lipton, Roger Cady, Headache: The Journal of Head and Face Pain

Lectures

InjectionED: Advanced Injection Training for Pain Disorders of the Head, Neck & Face
Cvent Online Event Registration Software, San Diego, California - 12/1/2012
2012 Best Practices in Primary Care
Primary Care Education, Irving, Texas - 6/29/2012

Press Mentions

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTIApril 2nd, 2022
Migraine and Genetics: Largest Study to Date May Inspire New TreatmentsFebruary 15th, 2022
Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute AttacksJune 16th, 2021
Join now to see all